Previous studies report that the augmented levels of PRDX1, PRDX3 and PRDX6 were associated with cisplatin resistance status for erythroleukemia, breast cancer and ovarian carcinoma [28, 29]. This evidence concerns the gene PRDX3 and breast carcinoma.